Structure–activity relationship and crystallographic studies on 4-hydroxypyrimidine HIF prolyl hydroxylase domain inhibitors
The 2‐oxoglutarate‐dependent hypoxia inducible factor prolyl hydroxylases (PHDs) are targets for treatment of a variety of diseases including anaemia. One PHD inhibitor is approved for use for the treatment of renal anaemia and others are in late stage clinical trials. The number of reported templat...
Main Authors: | Holt-Martyn, JP, Chowdhury, R, Tumber, A, Yeh, T-L, Abboud, MI, Lippl, K, Lohans, CT, Langley, GW, Figg Jr, W, McDonough, MA, Pugh, CW, Ratcliffe, PJ, Schofield, CJ |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2019
|
Similar Items
-
Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors
by: Holt-Martyn, J, et al.
Published: (2019) -
Molecular and Cellular Mechanisms of HIF Prolyl Hydroxylase inhibitors in Clinical Trials
by: Yeh, TL, et al.
Published: (2017) -
Biochemical and biophysical analyses of hypoxia sensing prolyl hydroxylases from Dictyostelium discoideum and Toxoplasma gondii
by: Liu, T, et al.
Published: (2020) -
Inhibition of a viral prolyl hydroxylase
by: Langley, G, et al.
Published: (2019) -
Structural basis of prolyl hydroxylase domain inhibition by Molidustat
by: Figg, WD, et al.
Published: (2021)